Search

Displaying results 5711 - 5720 of 10000 in total
  1. Drug

    Ganstigmine

    go.drugbank.com/drugs/DB06525
    Experimental

    Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.

  2. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  3. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  4. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  5. Drug

    Polyquaternium-10 (400 cps at 2%)

    go.drugbank.com/drugs/DB11356
    Approved

    Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.

  6. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    Telratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is a small molecule drug. The usage of the INN stem '-tolimod' in the name indicates that Telratolimod is a toll-like receptor (TLR) agonist.

  7. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib has a monoisotopic molecular weight of 560.19 Da. … Tuxobertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Tuxobertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  8. Drug

    APT3111

    go.drugbank.com/drugs/DB06390
    Experimental

    APT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).

  9. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  10. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.